Section II (Amendments to the Claims)

Please amend claims 1-3, 5, 15, 19(a), and add new claim 22, as set out in the listing of claims 1-22 below.

1. (Currently Amended) A F_V antibody construct having variable domains ~~binding sites~~ for ~~an~~ CD16 ~~receptor~~ and [[a]] CD30 ~~surface protein~~ but no constant domains, and inducing a regression of Hodgkin's disease *in vivo*.

2. (Currently Amended) The F_V antibody construct according to claim 1, wherein the CD16 ~~receptor~~ is derived from natural killer cells (NK cells).

3. (Currently Amended) The F_V antibody construct according to claim 1, wherein the CD30 ~~surface protein~~ is derived from a member selected from the group consisting of: Hodgkin's disease ~~cells~~ or Reed-Sternberg cells.

4. (Previously presented) The F_V antibody construct according to claim 1, wherein one binding site is present each.

5. (Currently amended) The F_V antibody construct according to claim 4, encoded by the expression vector pK~~H~~D16-30 (DSEM 12960).

6. (Previously presented) The F_V antibody construct according to claim 1, wherein two binding sites are present for each.

7. (Previously presented) An expression vector, coding for the F_V antibody construct according to claim 1.

8. (Previously presented) The expression vector according to claim 7, which is pKID16-30 (DSM 12960).

9. (Previously presented) A transformant, containing the expression vector according to claim 7.

10. (Previously presented) A method of producing the Fv antibody construct according to claim 1, comprising culturing the transformant according to claim 9 under suitable conditions.

11. (Previously presented) A kit comprising:

(a) an F_V antibody construct having binding sites for an CD16 receptor and a CD30 surface protein

and/or

(b) an expression vector coding for said F_V antibody construct, and

(c) at least one auxiliary substance selected from the group consisting of buffers, solvents, carriers, controls and markers,

wherein one or more representatives of the individual components may be present.

12. (Previously presented) A method for lysis of cells expressing CD30 surface proteins, said method comprising contacting said cells with an F_V antibody construct having binding sites for an CD16 receptor and a CD30 surface protein.

13. (Previously presented) A method according to claim 12, wherein the cells are tumor cells.

14. (Previously presented) A method according to claim 13, wherein the tumor cells are selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.

15. (Currently Amended) The F_V antibody construct according to claim 2, wherein the CD30 ~~surface protein~~ is derived from a member selected from the group consisting of: Hodgkin's disease ~~cells or~~ and Reed-Sternberg cells.

16. (Previously presented) An expression vector, coding for the F_V antibody construct according to claim 15.

17. (Currently amended) A method for lysis of cells expressing CD30 surface proteins, said method comprising contacting said cells with an F_V antibody construct having binding sites for an CD16 receptor and a CD30 surface protein, wherein the CD16 receptor is derived from natural killer cells (NK cells), and wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.

18. (Previously presented) A transformant, containing the expression vector according to claim 8.

19. (Currently amended) The F_V construct of claim 1, wherein said F_V antibody construct comprises elements (a) and (b) joined via a petide linker:
(a) a VH domain of an anti-CD16 antibody and a VL domain of an anti-CD30 antibody, the domains being joined by a peptide linker; and
(b) a VH domain of an anti-CD30 antibody and a VL domain of an anti-CD16 antibody, the domains joined by a peptide linker.

20. (Previously presented) A method of treatment of a tumor comprising the step of administering the F_V antibody construct according to claim 1.

21. (Previously presented) The method of claim 20, wherein the treatment comprises the lysis of Hodkin's disease or Reed-Sternberg cells.

22. (New) The F_V antibody construct according to claim 1, wherein said F_V antibody is capable of inducing a more intense lysis of CD30 carrying cells *in vitro* than bimAbHRS-3/A9 (DSM ACC2142).